Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases

1st October 2019 Uncategorised 0

Driven by the idiopathic pulmonary fibrosis market, Boehringer Ingelheim’s Ofev finally hit blockbuster sales in 2018. An FDA nod in a rare lung disease, Ofev is targeting even more small indications to add to its portfolio.  

More: Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases
Source: fierce